, ,800U cDNA 498 C 2230 H 3357 N 633 O 718 S 50 52, ,000 Glycoprotein (molecular weightca.64,000) consi
|
|
|
- ともみ たけくま
- 5 years ago
- Views:
Transcription
1 審議結果報告書 平成 19 年 12 月 4 日医薬食品局審査管理課 [ 販売名 ] リコモジュリン点滴静注用 [ 一 般 名 ] トロンボモデュリンアルファ ( 遺伝子組換え ) [ 申 請 者 ] 旭化成ファーマ株式会社 [ 申請年月日 ] 平成 18 年 8 月 29 日 [ 審議結果 ] 平成 19 年 11 月 22 日に開催された医薬品第一部会において 本品目を承認して 差し支えないとされ 薬事 食品衛生審議会薬事分科会に上程することとされた なお 本品目は生物由来製品に該当し 再審査期間は 8 年とし 原体及び製剤 ともに毒薬又は劇薬に該当しないとされた
2 , ,800U cDNA 498 C 2230 H 3357 N 633 O 718 S 50 52, ,000 Glycoprotein (molecular weightca.64,000) consists of 498 amino acid residues (C 2230 H 3357 N 633 O 718 S 50 molecular weight52,124.58) produced in Chinese hamster ovary cells by expression of cdna encoding amino acid residues at position of human thrombomodulin Thrombomodulin Alfa (Genetical Recombination) 1
3 β-hydroxyl Asn(Asn 324 ) 2
4 (a) (b) (c) O 3
5 , Disseminated Intravascular CoagulationDIC DIC DIC DIC DIC DIC DIC DIC 7 DIC U/kg 30 4
6 , ,800U DICDIC U/kg Disseminated Intravascular CoagulationDIC DIC DIC Biologicals; 30, ,
7 rhtmαhtm cdna CHO 498 C 2230 H 3357 N 633 O 718 S 50 52, ,000 5 Asn 29 Asn 97 Asn 98 Asn 364 Asn 391 N 7 Ser 287 Ser 474 Ser 480 Ser 482 Ser 485 Thr 486 Thr 488 O 46 Cys rhtmα cdna cdna TMJ2 TMD123TMD123 cdna SV40 psv2tmd123 psv2tmd123 psv2dhfr DHFR DHFR CHO MTX MTX rhtmα MCBMCB WCB 2 MCBWCB in vitro CAL MCB WCB CAL MTX MTX NT MTX NT NT rhtmα NT 1 rhtmα rhtmα µg/10 6 cells/day µg/10 6 cells/day µg/10 6 cells/day DNA NT DNA kb NT kb 6
8 mrna RT-PCR cdna MCB WCB CAL kb kb NT NT NT cdna rhtmα 2-2 MCB WCB CAL NT S L NT 1 NT NT NT In vitro VeroMRC-5CHO-K1 NT In vivo NT NT NT NT NT 2 NT NT MCB CAL WCB WCB MCB 1 MCB MCB WCB MCB MCB WCB WCB in vitro in vivo 1 BT Bovine viral diarrhea virusbovine adenovirus type 3Bovine parvovirusinfectious bovine rhinotracheitis virusbovine parainfluenza virus type 3 2 PT1 Porcine parvovirus 7
9 3 WCB 2-3 cells/ml L 2-3 ± L/ cells/ml µm in vitro MRC5VeroCHO-K1 U/mL EU/mL 2-3 *) 1L ml 1L ml * Medium 4 rhtmα 1 1 ph ± 2 ph 2 mg/ml 2 2 rhtmα 3 3 mg/ml 3 3 nm 0.22µm 20±5 AEXC AFCCEXC SEC
10 2-4 APC IgG ELISA IgG ELISA ELISA DNA IgG AEXC AFC CEXC SEC AFC rhtmα S L XC In vitro MRC-5VeroNIH-3T3 In vivo MAP 3 4 Bovine testiclebovine turbinatevero Rodent ParvovirusMouse parvovirusprospect Hill virus 4 Bovine respiratory syncytial virus BRSVBovine viral diarrhea virus BVDVRabies virusbluetongue virus type17reo 3Bovine parvovirus BPVBovine adenovirus BAV 9
11 rhtmα in vivo passage A rhtmα SDS-PAGESDS-PAGEpH AFC AFC 5 MCBWCB / MCBWCB / MCBWCB CAL CHO 2.12 in vitro MRC5VeroCHO-K1 ICH Q5A CHO XMuLVXenotropic murine leukemia virus PRVPseudorabies virus 3 Reo 3 MVMMinute virus of mice PRV XMuLV Reo 3 MVM / DNA/ env RNA/ env RNA/ env DNA/ env AEXC AFC CEXC ph nm
12 rhtmα 2-5 in vivo passage rhtmα in vitro MRC-5VeroNIH-3T3 MAP 6/ L CEXC A rhtmα 2 B C AC C D D L L E nm CEXC F E F mmol/l mmol/l G G G L L L H H G H G H G H 11
13 2 1 N C MALDI-TOF/MS MALDI-TOF/MS SDS-PAGEMALDI-TOF/MS SDS-PAGE RP-HPLCSECAEXC C cdna SDS-PAGE 1 SDS-PAGE MALDI-TOF/MS 64,000 N Ala Ala LC/MS Ala ± ±C 2 Gly 498 Gly LC/MS 46 Cys 23 Cys 12 -Cys 17 Cys 34 -Cys 149 Cys 78 -Cys 115 Cys 119 -Cys 140 Cys 157 -Cys 206 Cys 227 -Cys 238 Cys 234 -Cys 247 Cys 249 -Cys 262 Cys 270 -Cys 278 Cys 274 -Cys 290 Cys 292 -Cys 305 Cys 311 -Cys 322 Cys 318 -Cys 331 Cys 333 -Cys 344 Cys 351 -Cys 360 Cys 356 -Cys 370 Cys 372 -Cys 386 Cys 390 -Cys 395 Cys 399 -Cys 407 Cys 409 -Cys 421 Cys 427 -Cys 437 Cys 433 -Cys 446 Cys 448 -Cys nm SDS-PAGE pi pi rhtmα 1 rhtmα 12
14 rhtmα 1 U C S-2366L-Pyroglutamyl-L-prolyl-L-arginine-p-nitroaniline hydrochloride p-rhtmα 1 U 1 0.1µmol p-biologicals 2002; 30, 69-76rhTMα 1mg U rhtmα C C rhtmα K d 4.0nmol/LrhTMα C K m 5.1µmol/Lk cat 48min 1 N 5 O 7 N 2 O 1-1 SEC AEXC rhtmα AEXC rhtmα SDS-PAGE rhtmα SEC AEXC rhtmα SEC rhtmα Native-PAGE SEC AEXC
15 -3 DNA IgG 2 SDS-PAGE IEFpH SECAEXCDNA IgG 3 G L2 Lot No H L1 Lot No 20±5 36 5±3 6 25±2 3 20±2 2,500lx 120 lxhr ml ml ml µl 36 5±36 25±23 SECAEXC SDS-PAGE 20± mmol/l ph mmol/l rhtmα rhtmα L- 6,400U mg 14
16 2-7 G mmol/l C 2-7 A B C D 0.1mg640U 1mg6,400U 1mg6,400U 2mg12,800U 12,800U rhtmα 0.1 mg 1 mg 1 mg 2 mg 12,800 U mg mg L- 20 mg 20 mg 40 mg 40 mg D D G G G H 2 L- ph 0.22µm PVDF g± rhtmα ph SEC 4 10 / 3 Lot No. 25±260RH5RH36 15
17 40±275RH5RH6 60±23 20±22,500lx 120 lxhr SDS-PAGE 36 SEC SDS-PAGE ,000lx SDS-PAGEIEF SECAEXC 1 U mg mg ml Lot No.TS Biologocals; 30:69-76, mg/ml ml/ RP-HPLCN MALDI-TOF/MS 16
18 SECAEXC Lot No. Lot No. 1AFC rhtmα rhtmα 1mL A C XuMLV rhtmα AFC rhtmα XMuLV / RNA/ env A AFC CEXC ph nm AEXC AFC AEXC PRVReo3MVMXMuLV AFC Reo3MVM XMuLV 17
19 3 rhtmα rhtmα rhtmα rhtmα rhtmα rhtmα AEXC SEC rhtmα 4 N N pi 18
20 C C nmol/L 2nmol/L C 10µmol/L K d 4.0nmol/L 0.5µmol/L C C n=3 C µg/mL C C n=2 2 FVa µg/mL tissue factortf FVa 50%IC µg/mL FVa FVa 0.1µg/mL FVa 50% 2.6µg/mL FVa TF CaCl µg/mL IC µg/mL C % S % AT % C S C 27% 19
21 S 20% C S 10% 1µg/mL AT TF TF CaCl µg/mL0.0110µg/mL 0.160µg/mL IC µg/mL IC U/mL 20% 80%IC 80 /IC n=3 TF TF CaCl 2 5 CAPCAT AT ATAT µg/mLAPC TF 5 IC µg/mL0.030µg/mL0.15µg/mL 0.58µg/mL0.037U/mL 0.065IU/mL APC IC 80 /IC APC C 3 TCT TCT µg/mL U/mL TCT
22 APC TCT 2 8.2µg/mL6.7µg/mL 0.4µg/mL0.15µg/mL0.25U/mL 0.74 IU/mL IC 50 ±24±4.5nmol/L1.5±0.3µg/mL IC ±0.7 nmol/l97±20 nmol/l0.08±0.02u/ml 0.15±0.03IU/mL n= µg/mL 4DIC TFDIC1TF Sprague-Dawley 89 TF150mg/kg 1 DIC DIC TAT APTTPT FDP D- 6406,400U/kg0.1 1mg/kgTF 30300IU/kg 330mg/kg 0.33mg/kg TF 1 Control TF Normal DIC 1,900U/kg 0.3mg/kg PT 6,400U/kg1mg/kg TATFDP D- APTT 30IU/kg/hr 100IU/kg/hr TAT PT 100IU/kg/hr D-300IU/kg/hr APTT 0.3mg/kg/hr FDP D-n=56 TFDIC4TF Sprague-Dawley g TF100mg/kg 4 DIC DIC 1,900U/kg0.3mg/kg 300U/kg n=781,900u/kg0.3mg/kg 21
23 300U/kg µg/mL U/mL TFDIC1TFAT Sprague-Dawley g TF150mg/kg 1 DIC DIC AT 6406,400U/kg0.11mg/kg 30100U/kg TF 6,400U/kg 1mg/kg 100U/kg DIC n=412 Sprague-Dawley g AT 20mg/kg 1 6,400U/kg1mg/kg 100U/kg TF 90mg/kg 1 AT AT92 57% 6,400U/kg1mg/kgTF 100U/kg n=56 LPSDIC4LPS Wistar 67 LPS 055:B5 50mg/kg 4 DIC DIC APTT PT FDP GFD 1,90019,000U/kg mg/kg U/kg LPS 4 DIC FDP 6,400U/kg 1mg/kg1,900U/kg0.3mg/kg 1,900U/kg0.3mg/kg 200U/kg GFD 6,400U/kg 400U/kg n=617 TFDIC0.5TF kgTF50mg/kg 0.5 DIC DIC TAT FDP C APTT PT 6.46,400U/kg mg/kg 540U/kg TF TATFDP C APTTPT APTT TAT APTT 640U/kg0.1mg/kg 20U/kg TAT 64U/kg 0.01mg/kg 20% 70%ED 70 /ED
24 n= µg/mL 5DIC TFDIC0.5TF Sprague-Dawley 89 TF50mg/kg 0.5 DIC TF 1901,900U/kg mg/kg U/kg/hr U/kg0.1mg/kgTF U/kg/hr 300U/kg/hr n=10 6DIC LPSDIC24LPS Sprague-Dawley 7 LPS 055:B5 30mg/kg 24 DIC LPS 19,000U/kg3mg/kgLPS 1,900U/kg/hr 0.3mg/kg/hr 56%14/2592%23/25 GPT GOT C APC FVa Fa 2 1TAFI TAFI Sprague-Dawley 56nmol/L2.9µg/mLCaCl 2 TAFI TFDIC0.5TFTAFI Sprague-Dawley7TF1.9U/kg0.5 DIC6,400U/kg1mg/kg TFTAFI TATn=6 23
25 APTTPTXa µg/mLC APTT APTT2 100µg/mL1,000µg/mL Sprague-Dawley320420g13,000 51,000U/kg28mg/kg100400U/kg 1526,000U/kg4mg/kg200U/kg n=717 4DIC CLP-αTNF-α -6IL C57BL/681020% CLP19,000U/kg3mg/kgCLP 117CLP612 TNF-αIL-6CLP744% TNF-αIL-6n=483%n=18 LPSDIC3LPS-1β IL-1β Sprague-Dawley7LPS055:B5 3.75mg/kg3DIC 19,000U/kg3mg/kgLPSLPS 1,900U/kg/hr0.3mg/kg/hrLPS IL-1β770pg/mL 482pg/mL ddy5619,000u/kg3mg/kg 1Irwin open-field5 24
26 thiopental sodium 35mg/kg 5pentetrazol65125mg/kg Wistar6719,000U/kg3mg/kg 1Irwin Sprague-Dawley81,900U/kg0.3mg/kg 19,000U/kg3mg/kg190,000U/kg30mg/kg herg herg µg/mL kg19,000U/kg 3mg/kg kg19,000U/kg3mg/kg kg64,000U/kg10mg/kg 0.53pH Hartley250g10100µg/mL mol/l mol/l mol/l mol/l 24ddY5 619,000U/kg3mg/kg
27 Wistar6719,000U/kg3mg/kg 5 4 1APTT APTT13µg/mL0.168U/mL 0.11IU/mL0.1122µg/mL µg/mL 30 C Thromb Haemost; 70: J Biol Chem; 270: APC 15 Chest; 124(3 Suppl): 26S-32S U/kg 0.06mg/kg IC 50 90ng/mL TF DIC 270ng/mL DIC IC 50 90ng/mL DIC 30 C DIC DIC DIC DIC 26
28 ELISAenzyme-linked immunosorbent assay 125 I U/kg50µg/kg α β T 1/2α T 1/2β hr ,600U/kg µg/kg mL/kgCL mL/hr/kg AUC C ,600U/kg µg/kg mL/kgCL mL/hr/kg AUC C 0 320U/kg50µg/kg 2 C max AUC C max 320U/kg50µg/kg AUC C 0 T 1/2β CL 125 I- 320U/kg50µg/kg U/kg50µg/kg ,00038, ,000U/kg26 18mg/kg ,3003,800 13,000U/kg mg/kg C 5min AUC 0-24hr I- 320U/kg50µg/kg
29 125 I- 125 I 125 I I- 320U/kg50µg/kg I- 320U/kg50µg/kg 125 I- 320U/kg50µg/kg I- 320U/kg50µg/kg I I- 320U/kg50µg/kg ,600U/kg µg/kg
30 /6 320U/kg 50µg/kgT 1/2α hrT 1/2β hr T 1/2α T 1/2β hr Vd I Vd 2 Vd 1 Vd 1 Vd ,000380,000 1,200,000U/kg mg/kg 5 1,200,000U/kg 180mg/kg ,200,000U/kg180mg/kg 1 2 1,200,000U/kg180mg/kg 2 1,200,000U/kg180mg/kg
31 1 13,00038, ,000U/kg26 18mg/kg ,000U/kg ,000U/kg 1 120,000U/kg18mg/kg 2 1 GOTGPT 1 38,000U/kg/6mg/kg/ ,300 3,800U/kg mg/kg 1 1 3,800U/kg0.6mg/kg 2 3,800U/kg/0.6mg/kg/ 1 1,3003,80013,000 38,000U/kg mg/kg 1 1 1,300U/kg 3 5 1,300U/kg 1 13,000U/kg2mg/kg 1 38,000U/kg6mg/kg 2 38,000U/kg6mg/kg 2 13,000U/kg 2mg/kg 1 13,000U/kg2mg/kg 1 38,000U/kg6mg/kg 1 3,800U/kg0.6mg/kg 13,000U/kg2mg/kg 3,800U/kg0.6mg/kg ,000U/kg2mg/kg ,000U/kg6mg/kg 3 3,800U/kg0.6mg/kg GOTGPT 38,000U/kg6mg/kg 2 13,000U/kg2mg/kg 3,800U/kg0.6 mg/kg 13,000U/kg2mg/kg 1 1,300U/kg/ 0.2mg/kg/ 6 4 1,3003,800 13,000U/kg mg/kg
32 3,800U/kg 0.6mg/kg 1 13,000U/kg2mg/kg ,000U/kg 2mg/kg ,000U/kg2mg/kg ,800U/kg 0.6mg/kg 1 13,000U/kg2mg/kg 2 Fe 3,800U/kg0.6mg/kg 1 13,000U/kg2mg/kg 2 3,800U/kg0.6mg/kg 3,800U/kg 0.6mg/kg 13,000U/kg2mg/kg 1 13,000U/kg2mg/kg 1 1, ,800U/kg0.6mg/kg 27 13,000U/kg 2mg/kg 1 C 5min AUC 0-24hr 1,300U/kg/0.2mg/kg/ Don D-6 in vitro ,000U/kg18mg/kg ,000U/kg18mg/kg 13,00038, ,000U/kg26 18mg/kg ,000U/kg 6mg/kg ,000U/kg 31
33 18mg/kg ,000U/kg6mg/kg 38,000U/kg6mg/kg 7 120,000U/kg18mg/kg 13,000U/kg/2mg/kg/ 38,000U/kg/6mg/kg/ 13,000U/kg/2mg/kg/ 13,000U/kg2mg/kg ,00038, ,000U/kg26 18mg/kg ,000U/kg6mg/kg 2 120,000U/kg18mg/kg 22 38,000U/kg 6mg/kg 1 120,000U/kg18mg/kg ,000U/kg18mg/kg 38,000U/kg6 mg/kg 13,000 38,000U/kg2 6mg/kg 120,000U/kg18mg/kg120,000U/kg18mg/kg 120,000U/kg18mg/kg 13,000U/kg2mg/kg 3,800 13,000U/kg0.6 2mg/kg ,000U/kg2mg/kg 2 38,000U/kg6mg/kg 3,80013,000 32
34 38,000U/kg0.62 6mg/kg ,000U/kg6mg/kg ,000U/kg6 mg/kg4/ 1 38,000U/kg(6mg/kg) 13,000U/kg/2mg/kg/ 3,800U/kg/0.6mg/kg/ 38,000U/kg/6mg/kg/ ,700 U/kg1.2mg/kg 1/3 7,700U/kg1.2 mg/kg 1,300 3,800 7,700U/kg mg/kg ,700 U/kg 1.2mg/kg 3 2 7,700 U/kg1.2mg/kg ,800U/kg/0.6mg/kg/ ,000U/kg6mg/kg 3,80013,000U/kg 38,000U/kg0.62 6mg/kg ml/kg ,000 U/kg6mg/kg ,000U/kg2mg/kg ,000U/kg6mg/kg ,000U/kg 2mg/kg 5 38,000 U/kg6 mg/kg 33
35 3,800U/kg/0.6mg/kg/ 3,800U/kg/0.6mg/kg/ 13,000U/kg/ 2mg/kg/ ,900 19,000U/mL mg/mL 0.05mL/ ()3mg/mL ASA ASA PCA ASA mg/14 1mg/ PCA 12 ASA mg/ ASA PCA PCA mg/ 24 1mg/ 64,000 DNA in vitro 34
36 DIC ELISA ,900U/ mg/ 2 C max 190U/ ,900U/ 48 C max ± 10.15± ± ±5.16ng/mL AUC AUC inf ± ±31.731,074.72± ,030.89± nghr/ml T 1/2α hrt 1/2β hr CL ml/hr/kg ,900U/0.3mg/ 1 C ±5.43 ng /ml±auc inf ±
37 nghr/mlt 1/2α 3.37±2.27 hrt 1/2β 19.82±2.10 hrcl 1.49±0.24 ml/hr/kg ± ±10.3% C ,300U/0.2mg/ C max AUC inf 93.29±4.62ng/mL 2,143.09±204.43nghr/mL T 1/2α 3.94±1.83hrT 1/2β 18.73±4.25hrCL 1.40±0.31mL/hr/kg DIC U/kg mg/kg ± ± ±237.9ng/mL ± ± ,730.7±445.1ng/mL ± ± ±313.7ng/L 10.6± ± ±6.8ng/mL 4 7 DIC DIC ng/mL ng/mL 500ng/mL ng/mL 70% 380U/kg0.06mg/kg6 36
38 PPK kg3190kg 1.14 mg/dl mg/dl NONMEM 79 / GOT GPT CV Vd 34.4%CL 31.3% Vd WT 1.43 HT CL WT AGE HT1 or 0 AGE1 or 0 WTkg PPK CL 16% 43% 1 DIC 30 I DIC 30 37
39 I 2 2 C max 30 C max C max PPK PPK PPK 1 I 2 PPK AUC CL AUC 3509 nghr/ml α AUC 436 nghr/ml 12β AUC 3,073 nghr/ml 88% 1- PPK 1- PPK 38
40 2- α 1-2 PPK PPK 0.25 Tukey P-value 0.05 / 1.2 mg/dl Cockcroft and Gault 40mL/min 20mL/min CL PPK U/kg 0.06mg/kg 4mg/dL 1mg/dL C max 1.2 PK
41 kg kg15 48kg 4mg/dL mg/dL PPK PPK CL 15% 1 130U/kg 130U/kg DIC PPK 25 4mg/dL PPK PPK 40
42 ng/mL 1,000ng/mL 100ng/mL 1000ng/mL 100ng/mL APC IC 50 90ng/mL IC I I DIC * mg/0.2mg/ mg/1 DIC DIC mg0.61.2mg1.22.0mg mg/ : 0; ; ; ; 83.3 DIC DIC DIC mg0.02mg0.06mg/kg mg/kg U/kg/hr 6 24 DIC * 50kg 1,90019,000U/0.33.0mg/38380U/kg mg/kg : 0.006mg/kg mg/kg mg/kg 67.6% DIC Woolson-Bean 66 1 vs ,900U/ mg/ 2431,300U/0.2mg/
43 30.1mg10.3mg mg 20.3mg120.2mg ,900U/0.3mg/ ±45.3± ± ±14.6% (%) (hr) 42
44 DIC DICDIC mg// 0.6mg// ,900U/0.3mg/ 3,800U/0.6mg/ 13,800U/ 0.6mg/ 7,700U/1.2mg/ 27,700 U/1.2 mg/ 13,000U/2.0mg/ 313,000U/2.0mg/ 19,000U/3.0mg/ DIC DIC %1/1 16.7%1/6 0%0/2 100%5/5 43
45 100%3/3 16.7%1/6 60.0%3/5 66.7%2/3 100%3/3 11.1%1/9 42.9%3/7 66.7%2/3 75.0%3/4 50.0%5/ %5/9 83.3%10/12 DIC 50.0%2/4 30.0%3/ %3/9 75.0%9/ %3/4 40.0%4/ %5/9 83.3%10/ %1/4 30.0%3/ %3/9 50.0%6/ /4 0/13 1/9 1/ DIC DICDIC 92 38U/kg0.006mg/kg 1,900U/0.3mg/130U/kg 0.02mg/kg 6,400U/ 1.0mg/380U/kg0.06mg/kg19,000U/3.0mg/ FDP 4 FDP FDP mg/kg mg/kg 33/ %0.02mg/kg 31/ %0.06mg/kg 39/ % 0.006mg/kg mg/kg mg/kg 0 44
46 mg/kg mg/kg 39.3%11/ mg/kg 60.7%17/ mg/kg 67.6%23/34 Cochran-Armitage p= mg/kg 0.02 mg/kg 0.06 mg/kg % 14.30% 28.60% 21.40% 10.70% 39.30% % 17.90% 21.40% 10.70% 7.10% 60.70% % 20.60% 8.80% 8.80% 14.70% 67.60% % 17.80% 18.90% 13.30% 11.10% 56.70% DIC mg/kg 0.02 mg/kg 0.06 mg/kg / / / / / / / / / / / /90 DIC / / / /94 DIC 5 2 DIC DIC DIC DIC mg/kg mg/kg mg/kg
47 mg/kg mg/kg mg/kg mg/kg 14/ %20/ / ALP GOT GPT mg/kg 15/ / / mg/kg mg/kg mg/kg DIC 0.06mg/kg/ DIC DICDIC DIC DICDIC mg/kg/
48 8U/kg/hr DIC DIC Full Analysis SetFAS FAS Per Protocol SetPPS %PPS PPS % % DIC FAS DIC 224 DIC DIC DIC FAS DIC DIC DIC DIC 5 2 DIC DIC DIC FAS DIC 100 DIC Woolson-Bean DIC FAS -%- 95% 95%
49 7 7 FAS % 95% Mantel-Haenszel χ P FAS 95% 95% Mantel-Haenszel χ :1 P FAS 95% 95% FDPµg/mL PICµg/mL ^4/µL D-µg/mL ^4/µL α2pi% mg/dl C% PT PAI-1ng/mL APTT µg/ml TATng/mL AT% % 70.7%82/ /116 48
50 53.462/ %83/ % 69/ / / / GOT 6.07/ /116 GPT 5.26/ / / / / / / / /115 LDH 3.54/115 GOT 3.54/115 GPT 3.54/ / / /116 29/ /116 9/ %1/112 vs. 5.5%6/ %1/112 vs. 5.5%6/ %1/112 vs. 5.5%6/110 AL-P 1.0%1/103 vs. 4.9%5/102 LDH 0 0/109 vs. 3.8%4/106 GOT 6.5%7/107 vs. 3.8%4/ %5/89 vs. 1.2%1/84 4.3%4/92 vs. 1.1%1/90 3.2%3/93 vs. 0.0%0/ / / / / %6/ %6/ / / / / / / /116 49
51 1.74 7/ DIC DIC DIC DIC DIC DIC DIC DIC DIC 1983;38: DIC 1520% 5% 4.11 DIC DIC DIC DIC DIC Principles of Internal Medicine 16 th ed.mcgraw Hill DIC DIC DIC
52 4.12DIC DIC DIC 1 DIC U/Levi M, et al. N Engl J Med 1999; 341: DIC U/kg/ 21 pp DIC ,000U J.Pediatr; 91: JAMA; 286: C PROWESS 15,000U/N. Engl. J. Med; 344: DIC 7 10U/kg/hr; 23: C DIC 8U/kg/hrInt. J. Hematol; 75: DIC 10U/kg/hrThromb. Res; 72: DIC 8U/kg/hr 8,64012,480 U// DIC 10,000U// DIC. 1. : ; p DIC Blood; 75: U/kg/hr DIC AT AT AT 50 2DIC DIC DIC
53 , 54 : , 62 : DIC Clin Appl Thromb Hemost; 11: DIC Crit Care Med; 34: ISTH DIC overt-dic DICCrit Care Med; 32: ISTH overt-dic DIC 1988 overt-dic DIC ISTH overt-dic DIC DIC ; 31: DIC 1 DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC FDP 3 PT 2 DIC DIC DIC DIC DIC DIC 52
54 DIC DIC FDP 3 FDP DIC DIC FDP ; 18: FDP ;pp DIC DIC FDP DIC FDP CT DIC DIC DIC DIC DIC DIC DIC ISTH overt-dic Am. J. Hematol; 4: DIC DIC DIC 7 DIC DIC DIC DIC DIC 53
55 3 DIC DIC 28 1 DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC 7 DIC 28 DIC DIC 10.0%6/ %23/39 DIC DIC 8.6%6/ %16/55 7 DIC 28 DIC 3.1%1/ %11/16 DIC 7.1%3/ %8/22 DIC DIC DIC DIC 7 DIC DIC DIC DIC DIC DIC 7 3 FDP515.5µg/mLD µg/mL ATTAT ng/mLα2 54
56 PIC µg/mLSFMC µg/mL DIC DIC DIC TAT DIC DIC TAT 4 DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC Woolson-Bean DIC 95% % 95 5% DIC DIC DIC DIC N Engl J Med; 341: DIC DIC DIC 55
57 DIC FAS DIC DIC FAS 60/ / / / % 5/ % 0/ / / / / / / % 23/ / / / / / DIC DIC DIC -1 FAS DIC DIC FAS DIC 95 DIC FDP 7 7 DIC LOCF FDP DIC FAS DIC DIC 95()()
58 -3 DIC DIC DIC ; 16: DIC DIC DIC FAS D- FDP D-/FDP FDP DIC DIC 7 DIC 2 3 DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC 2 DIC DIC DIC 95()()) U/kg0.06mg/kg DIC DIC 60%3/5 DIC 4 DIC DIC 2 SIRS DIC DIC 85 SIRS 3 1 ; 16: SIRS 3 DIC 2 DIC DIC 7 DIC 3 4 DIC DIC 2 3 DIC DIC 3 DIC DIC 57
59 U/kg0.06mg/kg DIC 60.0%3/5 DIC -4 overt-dic ISTH overt-dic Crit Care Med; 32: DIC FAS 227 overt-dic DIC 7 DIC 4 5 overt-dic overt-dic DIC overt-dic Fibrin-related marker overt-dic Fibrin-related markerd- 0 1µg/mL1µg/mL 2 10µg/mL10µg/mL 3 PT overt-dic DIC Overt-DIC DIC DIC Overt-DIC 95% U/kg0.06mg/kg 35 overt-dic DIC 68.8% 11/ %4/4 42.9%3/7 50.0%1/2 ) -5 LOCFlast observation carried forward DIC
60 8 LOCF DIC 38U/kg0.006mg/kg 35.3%12/34 130U/kg 0.02mg/kg 45.2%14/31 380U/kg0.06mg/kg 54.3%19/35-6 FFP DIC FFP C S 17 9 DIC FFP FFP FFP DIC FFP DIC FAS FFP 10U 10U 95 DIC 37/ / / / / / ( ) DIC 26/ / / / / / PPS FDP FDPµg/mL /µl mg/dl PT TATng/mL
61 PICµg/mL D-µg/mL α2pi% C% PAI1ng/mL SFMCµg/mL AT% TAT 4 13 TAT TAT FAS 5 ART-123 ART-123 DIC 186 ART ART-123 DIC ART
62 ART DIC % vs % % vs % %vs % %vs % DIC DIC DIC DIC DIC %50/ %65/115 61
63 p=0.0487fisher %64/ %75/115 p= %2/ %7/ DIC / N=116 N= AMLM3 62
64 α 2 PI DIC α 2 PI ART ART ART ART
65 88 1 CBS GmIgGHCP 79 CBS0 migg1 HCP1 88 CBS1 migg1 HCP2 85 CBS1 migg1 HCP0 HCP FFP DIC DIC 3 DIC DIC ; 23: vs DIC Thromb Res; 72:
66 6 6.6 vs ATJAMA; 286: AT38.9 vs CAPC DIC Int. J. Hematol; 75: APC20.4 vs APC N. Engl. J. Med; 344: APC24.7 vs DIC DIC ATJAMA; 286: AT44.9 vs DIC DIC DIC 2001 ISTH SSCDIC DIC Thromb. Haemost; 86: DIC DIC DIC DIC 2 Harrison s Principles of Internal Medicine 16 th ed.mcgraw Hill DIC DIC DIC DIC DIC DIC DIC DIC AT Blood; 75: ; 8: ; 23: ; 124: ; 65: DIC 65
67 AT 4 1 DIC DIC DIC DICDIC DIC 4 DIC DIC DIC DIC DIC DIC DIC TF Levi M, et al. N Engl J Med; 341: DIC DIC DIC DIC ; 8: ; 65: DIC DIC DIC DIC DIC DIC DIC DIC DIC TAT DIC DIC DIC 28 DIC DIC 25.01/4 vs. 66
68 DIC 53.8%7/13 DIC DIC DIC DIC 11, pp DIC 54 DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC 67
69 DIC DIC DIC 3 2 C C C C 10% 4 DIC In vitro C C 30% C 10% ; 34(4): C C 10% DIC C 10% C DIC DIC In vitro C 10 C 10% 4 In vitro C 10% C 10% K C C 23 DIC C 68
70 C C 10% DIC C DIC C Wintrobe s Clinical Hematology 11 th edt.lippinvott Williams&Wilkins C 3 DIC DIC DIC DIC DIC ; 47: DIC DIC ; 47: DIC DIC DIC DICAML M3 4 DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC DIC 69
71 DIC DIC DIC DIC DIC DIC DIC DIC DIC 5 DIC DIC DIC DIC 6 DIC
72 0.06mg/kg 380U/kg 0.06mg/kg 67.6% 38U/kg 0.006mg/kg130U/kg0.02mg/kg380U/kg0.06mg/kg 3 130U/kg0.02mg/kg 380U/kg0.06mg/kg DIC DIC 380U/kg0.06mg/kg in vitro in vivo 380U/kg0.06g/kg mg/kg mg/kg DIC DIC 38130U/kg mg/kg U/kg mg/kg %0/4 15.4%2/13 0%0/8 20.0%2/ mg/kg 15.4%4/ %3/ %10/ mg/kg 380U/kg0.06mg/kg 2 71
73 DIC Thromb Haemost; 74: /352 DIC pre-dic DIC DIC DIC DIC pre-dic non-overt-dic 80 8 Thromb. Haemost; 78: pre-DIC DIC 6 7 DIC / %32/45 DIC DIC DIC
74 1 DIC DIC DIC DIC 6 DIC DIC 7 DIC TAT DIC TAT 7 4 DIC 130U/kg 0.02mg/kg ,700 U/1.2 mg/ 13,000U/2.0mg/ 28 DIC DIC 1 DIC 1 ART
75 1 DIC DIC ART ART-123 ART ,000 DIC
76 C 10% DIC ART-123 DIC 1. 2GCP DIC DIC DIC DIC DIC DIC DIC DIC 75
77 , DIC DICDICDIC DICDIC DIC DICDIC DICDICDIC DICDIC DIC DICDICDIC 2 DIC DIC DIC 76
78 4 DIC DIC DIC 1 DIC DIC DIC DIC DIC DIC DIC DIC U/kg0.06mg/kg 130U/kg0.02mg/kg 130U/kg 130U/kg 77
79 DIC 130U/kg DIC 130U/kg 7 DICDIC DIC 6 7 DIC1 1 DIC DIC 78
80 DIC DIC DIC 6 3 in vitro DIC 7 DIC DIC DIC DIC DIC DIC DIC DIC
81 3,000 1 C 10% DIC DIC DIC DIC DIC DIC DIC DIC DIC 80
82 DIC 2 MR DIC 1,000 3, , , MR DIC DIC DIC DIC MR DIC DIC Ser 482 Thr cells/ml cells/ml XuMLV XMuLV 81
83 pi pi ,900U/kg0.3mg/kg 19, 000U/kg3mg/kg U/kg ,000U/ 15,000U/ DIC ISTH ISTH vs vs GCP GCP 1 GCP GCP 1 82
84 GCP DIC DIC %1/1 16.7%1/6 0%0/2 100%5/5 100%2/2 16.7%1/6 60.0%3/5 66.7%2/3 100%2/2 11.1%1/9 42.9%3/7 66.7%2/3 66.7%2/3 50.0%5/ %5/9 83.3%10/12 DIC 33.3%1/3 30.0%3/ %3/9 75.0%9/ %2/3 40.0%4/ %5/9 83.3%10/12 0%0/3 30.0%3/ %3/9 50.0%6/ /3 0/13 1/9 1/
85 8 DIC U/kg 30 84
ŁRŁ¸•ñŁŁŁ‘
16 11 5 25mg 14 11 18 1 25mg 1 150,000 934 1 2 : 1-235-tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human γ1-chain Fc fragment), dimmer : : 1 235 236 467 G 1 γ1
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4)
1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET ibalf ii CVF i iibalf i ii iiibalf i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) ET CVF (5) (6) 3) (1)in vitro 2. 1)ONO-5046Na (1) (2) (3) (4)
ケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
untitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
i 1 2 MCB MCB WCB in vitro CAL in vitro CAL In vitro 5 In vivo
EU ICH ICH i 1 2 MCB 2 3 3 MCB WCB in vitro CAL 3 3 3 in vitro CAL 4 4 4 In vitro 5 In vivo 5 5 5 5 6 9 10 10 11 11 11 ii 11 12 12 13 13 13 14 16 17 17 17 19 1 in vivo BSE BSE DNA in vitro in vivo in vivo
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
untitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
エディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
（案－１）
薬食審査発 0930 第 1 号 平成 26 年 9 月 30 日 各都道府県衛生主管部 ( 局 ) 長殿 厚生労働省医薬食品局審査管理課長 ( 公印省略 ) 医薬品の一般的名称について 標記については 医薬品の一般的名称の取扱いについて ( 平成 18 年 3 月 31 日薬食発第 0331001 号厚生労働省医薬食品局長通知 ) 等により取り扱っているところであるが 今般 我が国における医薬品一般的名称
,328 C 6426 H 9900 N 1700 O 2008 S , ,
2458 13 4 24 1 11 9 17 1,328 C 6426 H 9900 N 1700 O 2008 S 44 145,000 148,000 10 11 27 2 13 4 24 11 9 17 (1) CD20 B CD20 (2) infusion reaction infusion-associated symptom CD20 B 1 375mg/m 2 1 4 3 Heavy
1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
まえがき
JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------
< B C957491E48E86312E696E6464>
10 DDS New York Academy Renal Biochemistry (Elsevier) Glutathione (John Wiley & Sons) Antioxidants in Therapy and Preventive Medicine (Plenum) The Liver: Biology and Pathophysiology (Raven Press) NO SSC
温泉の化学 １
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
グリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
アクテムラインタビューフォーム
2009 2 6 876399 IF 1998 9 FAX 80mg 1 4mL 80mg 200mg 1 10mL200mg 400mg 1 20mL400mg JAN TocilizumabGenetical RecombinationJAN 200mg 80400mg 2007 9 10 2008 4 16 2007 12 21 2008 6 13 2005 6 13 2008 6 13 2009
1.9 一般的名称に係る文書 1.9 一般的名称に係る文書 国際一般名 (INN) thrombomodulin alfa(r-inn List54, WHO Drug Information, Vol.19, No.3, 2005) 一般的名称 (JAN) 一般的名称 (J
リコモジュリン点滴静注用 12800 トロンボモデュリンアルファ ( 遺伝子組換え ) 第 1 部 1.9 一般的名称に係る文書 1.9 一般的名称に係る文書 1.9 一般的名称に係る文書 1.9.1 国際一般名 (INN) thrombomodulin alfa(r-inn List54, WHO Drug Information, Vol.19, No.3, 2005) 1.9.2 一般的名称
用法 用量 発作性夜間ヘモグロビン尿症における溶血抑制 mg mg mg mg kg 30kg 40kg 20kg 30kg 10kg 20kg 5kg 10kg 1900mg mg mg mg
C EculizumabGenetical Recombination AMX 警告 1 2 禁忌 ( 次の患者には投与しないこと ) 1 2 組成 性状 ml mg mg mg mg mg ph ph mgml 効能 効果 発作性夜間ヘモグロビン尿症における溶血抑制 < 効能 効果に関連する使用上の注意 > 共通 1C5 C5b-9 b 発作性夜間ヘモグロビン尿症における溶血抑制 1 2 3 4
エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR
1996 papilloma virus 2001 Bowen2002 12 2003 2 2002 9 10 AIHA PSL1mg/kg BMAPRCA parvovirus B19 PVB19 DNA PCR PV IgM 4PVB19 PRCA MAPPVB19DNA DNA PRCA IVIG;20 50g/ IVIG PVB19AIHA steroid 15 20mg/day 2003
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
untitled
ORYZA CERAMIDE -PTPCDP8TP20CD -WSPWSP8 -LL0.8 -PCPC8PC20 -WSPCWSPC8 -LCLC0.8 Ver.13.0HS ORYZA CERAMIDE Ver.13.0HS 1. 2. 20 NMR 4 ( 1) 1 Ver.13.0HS HO CH 2 OH O O OH OH OH C CH CH H 2 NH C O R C H C H (CH
Microsoft Word - 14_LCMS_アクリルアミド
3--2-3-Iodo-2-propynyl butylcarbamate (IPBC) Carbamic acid, butyl-, 3-iodo-2-propynyl ester Iodocarb CAS 55406-53-6 C 8 H 12 NO 2 I C (g/cm 3 ) (mmhg) log P ow 281.09 (280.9910) 64 68 1.51 1.57 (20 C)
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR
ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
1999年3月作成(新様式第１版)
200622 19989 871313 1mL4mg JAN oxybuprocaine hydrochloridejan 2002621 20037 4 19667 1 FAX 2005 10 29607 05 1 63 () 103 2 3 49 111 4 Drug Safety Update 1. -------------------------------------1 2. -----------------------1
untitled
ver. 3.3JT EVENING PRIMROSE EXTRACT 1 - PMS 1 2 1 4 Oenothera laciniata Oenothera striata Oenothera biennis Oenothera erythrosepala - 2 80 60 40 20 0 1. 2 3 PGGPAC 2. 3 4 ESR3.5 10 5 /g 4 3 1 Helicobacter
「 （会の名称） 」のご案内
千葉県病院薬剤師会北部支部会員各位 16 年 2 月吉日 千葉県病院薬剤師会北部支部 学術講演会 北部支部長土谷隆紀謹啓時下ますますご清祥の段 お慶び申し上げます さてこの度 千葉県病院薬剤師会北部支部 学術講演会を下記の通り 開催させて頂く事となりました つきましてはご多忙中のこととは存じますが万障繰り合わせの上 ご出席賜りますようにお願い申し上げます 謹白記 日時 : 平成 28 年 4 月 15
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
gtf Wnt5a-Ror2 IL-8 in vitro Ozony Tron P. gingivalis SOD ELISA Location of main occluding areas and masticatory ability in patients with reduced occlusal support 12-Methacryloyloxydodecylpyridinium bromide
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
ライフサイエンス関連 コラーゲン・ゼラチン製品案内 2015.12
3 mg/ml ph 3 4 8 1 Type I-A Type I-P Type I-A Type I-C Type III Type III Type IV Type IV TEL 072-820-3079 FAX 072-820-3095 4 8 4 Type I-A 20mL 1 F-12 MEM 5mL 1 4mL 5 10F-12MEM DFDME F-12 1 1199 5 DMERPMI-1640
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75
ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm
![ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm](/thumbs/85/92935308.jpg "ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm")
1 186 186 (1) - 192 (2) (ISAintrinsic sympathomimetic activity) 199 (3) ( MSAmembrane stabilizing activity) 2 (4) 21 (5) 212 (6) 216 (7) 219 (8) 224 (9) (ASL-8123) - 229 (1) d-esl l-esl - 231 2 235 235
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
......IF
873959 CEREZYME injection IF20084 MR MR Drug Safety Update IF I. 1 3 2 3 II. 1 4 2 4 3 4 4 4 5 5 6 5 7CAS 5 III. 1 6 2 6 3 6 4 7 5 7 IV. 1 8 2 8 3 8 4 8 5 9 6 9 7 () 9 8 9 9 9 10 9 11 10 12 10 13 10 14
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
untitled
1 1 2 CADLIVE E-CELL 3 GEM CE/MS MGF WT MGF 4 2 WT E-Cell MASK 5 CE-MS, CE- TOFMS LC-MS 24, 5 9 2 0 6 3 CE-MS CE MS Soga, T. et al. (2002) Anal Chem. 74, 2233-2239 7 CE-MS 859 452, 269, 86 8 4 LC-MS 9
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
Providing Care for HIV-infected Woman Amneris E. Luque, MD SMH AIDS Center Medical Director 2002/07/01
Providing Care for HIV-infected Woman Amneris E. Luque, MD SMH AIDS Center Medical Director 2002/07/01 8000 6000 4000 2000 0 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 30 25
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
Microsoft Word - H18年度生命工学報告書 Astro ver.3
1. Rotavirus Norovirus Adenovirus Astrovirus Sapovirus 5 1) Human Astrovirus HastV 1975 Madeley Cosgrove EM RNA 30nm 5 6 Fig. 1 2) HastV 8 3 5 HastV ELISA Enzyme-Linked ImmunoSorbent Assay RIA Radio immunoassay
untitled
ORYZA OIL & FAT CHEMICAL CO., LTD. WHITE JELLY FUNGUS EXTRACT -P () Ver. 1.3SJ Ver. 1.3SJ 1. 3000 ph 1 Ver. 1.3SJ 1. 1 2. 3 2-1. 2-2. 2-3. 2-4. SOD 3. 7 3-1. in vitro 3-2. in vivo 3-3. in vivo 3-4. in
外因性内分泌攪乱化学物質調査暫定マニュアル（水質、底質、水生生物）
N- 1) 2) 1) GC/MS HPLC GC/MS 2) 0.01~0.05µg/l 0.5~50µg/kg GC/MS SIM GC/MS SIM GC/MS SIM a) b) -d 10 -d 10 -d 12 -d 12 c) d) 600 C 4 e) 1 99.999% f) a) b) - IX-1 - c) (ODS) 200-1,000mg 5ml 5ml 5ml d) e)
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
indd
18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,
21 60 Vol. 21 No
3040 90 2 Vol. 21 No. 81999 21 60 Vol. 21 No. 81999 3 4444444444444444444444444444444444444444444444444444444 1830 10 12 1010 18 80 32 4 Vol. 21 No. 81999 Vol. 21 No. 81999 5 6 Vol. 21 No. 81999 Vol. 21
ÿþ
インターロイキン インターロイキンは リンパ球や単球 マクロファージなどの免疫反応への寄与が知られる白血球から産生されることから 細胞間 ( inter-) 白血球 ( leukocyte -leukin) より Interleukin と名づけられました 現在までに 30 種類以上のインターロイキンが同定され 発見された順番に番号が付与されており 中にはケモカイン ( IL-8) やインターフェロン
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
untitled
er. 3.0SJ ver.3.0 SJ 3 2 1 ver.3.0 SJ 900 1200 () 400 2 ver.3.0 SJ OH OMe OMe O O O MeO O MeO OMe O O OMe O OMe OMe O O MeO O O H O O MeO OMe O H O OH OMe O CH 2 HO O O O O CH 3 OH HO OH OH HO OH O 1 3
19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40
A case of membranoproliferative glomerulonephritis accompanied with hyper IgM immunodeficiency Kenichiro SHIGEMOTO, Koji WADA, Naoki HAMAGUCHI, Akira HIRABAYASHI, Shunji TOI, Koji USUI, Michiko ARITA,
マニュアル第４版表紙PDF
5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.
Ⅱ6.3界面活性剤
6.3 6.3.1 6.3.1 6.3.1.1 (1) (2) a) JIS K 0557 A3 b) JIS K 8891 c) (5g/L) d) (10g/L)JIS K 8576 1g 100mL e) (7+993)JIS K 8951 f) JIS K 8322 g) 0.1g 100mL 30mL 1L 500mL6.8mL 50g 1L h) 1L 500mL6.8mL 50g 1L
日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
untitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
使用上の注意 1. 慎重投与 ( 次の患者には慎重に投与すること ) 1 2X X 重要な基本的注意 1TNF 2TNF TNF 3 X - CT X 4TNFB HBsHBcHBs B B B B 5 6TNF 7 8dsDNA d
2015 5 7 201410 28 TNF 阻害薬 TNFFab シムジア 皮下注 200mg シリンジ Cimzia 200mg Syringe for S.C. Injection セルトリズマブペゴル ( 遺伝子組換え ) 製剤 873999 22400AMX01488000 20132 20133 20155 20079 警告 1. 2. 1 2 X - CT 3. TNF 4. 1 禁忌
能書単頁9[1].5(2)
![能書単頁9[1].5(2)](/thumbs/87/96620151.jpg "能書単頁9[1].5(2)")
ips CytoTune -ips ver.1.0 1 I CytoTune ips 3 II 3 3 4 5 III CytoTune ips ips 6 6 6 6 7 1) 2) ips 8 ips 8 SeV 9 SeV 10 IV Q&A 11 V 12 12 VI...13 13...13 2 I CytoTune ips CytoTune ips 4 OCT3/4SOX2 KLF4c
3 1 2
Agilent 4200 TapeStation Agilent 4200 TapeStation 3 1 2 2 3 ScreenTape 3 Agilent 4200 TapeStation QC Agilent 4200 TapeStation Ready-to-use ScreenTape 8 PCR 96-well plate 1 96 1 qrt-pcr DNA RNA DNA / RNA
5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
細胞増殖測定細胞染色プロトコル
Cell Counting Kit Cell Counting Kit -8 3 Cell Counting Kit -F -Cellstain- -Cellstain- -Cellstain- Calcein-AM solution -Cellstain- CytoRed solution -Cellstain- BCECF-AM special packaging -Cellstain- -Cellstain-
untitled
T DAC8 2011 1 27 (DAC) DAC 11 DAC8 DAC8 T Leukemia. 2008, 22, 1026 1134. Clin. Cancer. Res. 2009, 15, 91 99. DAC8 1)DAC8 2) T T T-ALL 10 1 T-ALL 30~40% T CTCL 10 1 CTCL T ATLL 1 TLV-1 120 2,000 TLV-1 16~41%
24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD
Immunocompromised Children 24 RS24 24 RS 24 RSRespiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 1 RS 28 2935 12 6 RS BPD 246 1 1 CHD 24 24 24 2 RS [1] [1.1] RS 24 RS T DiGeorge Wiskott- Aldrich
中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
C VECS C F M kg A E W kg I A R. R. Gkg MGD MGD MGD MGD SPKMGD MGD MGD SPK SPK MGD MMP MMP MMP kg mmhg Intrascleral prosthesis : ISPISP ISP ISP ISP ISP ISP ISP ISP ISP mm mm ISP mm min mm min ISP mm min
秋田応用微生物研究会
13:00-13:10 13:10-13:30 13:30-13:50 (Tricholoma auratum) 13:50-14:10 14:10-14:30 14:30-14:50 14:50-15:10 α-msh 15:10-15:30 Lewis 15:30-15:50 15:50-16:10 16:10-16:30 (1) (2) ( ) (2) (1) (2) (3) (1) (2)
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
秋田応用微生物研究会
13:00-13:30 13:30-13:50 Pseudomonas aeruginosa 13:50-14:10 14:10-14:30 Bacillus polymyxa KT551 * * 14:30-14:50 14:50-15:10 15:10-15:30 15:30-15:50 Streptomyces kasugaensis RNA rpoz * ** ** * ** 15:50-16:10